PharmaTalkRadio

Latest Episodes:

How Partnering with Medical Research Charities is Key to Medicines Development Jan 09, 2019

Show notes

Medical research charities in the UK have been successfully integrating patient insight into their activities for over 10 years. In this session presented at the 2nd annual Patients as Partners Europe in January 2018, Claire Nolan, Research Involvement Manager, Parkinson's UK, and Chris MacDonald, Research Involvement Manager, Arthritis Research UK, explore a shift in attitiude towards pharmaceutical and medical research charity collaboration. They share how charities have developed their processes to strike a balance of delivering effective research outcomes whilst ensuring principled and meaningful patient involvement and how these experiences, resources, and processes can be used practically to support industry to put the needs and voice of patients at the centre of medicines development. The 3rd annual Patients as Partners Europe will be presented January 28-29, 2019 in London, UK. Find more information here.

Patients as Partners Europe 3rd Annual What to Expect in 5 Minutes Dec 24, 2018

Show notes

This 5 minute podcast summarizes what you can expect at the 3rd annual Patients as Partners EU conference. It is the only event in Europe that demonstrates how to involve patients throughout the entire medicines development life cycle to drive greater efficiencies in clinical research. It takes place January 28-29 at the Millennium Gloucester Hotel in the Kensington area of London. The program is co-chaired by GSK's Andrew Garvey, Global Patient Advocacy Lead and Servier's Dr Lode Dewulf, Chief Patient Officer. The conference kicks off with former professional English footballer and patient advocate, Geoff Thomas, in a keynote presentation on his journey through professional sports and his fight against cancer. For more information please contact www.theconferenceforum.org or contact us at service@tcfllc.org.

How Tesaro is Integrating the Patient in the Clinical Development Process Dec 12, 2018

Show notes

In this talk from the 5th annual Patients as Partners US conference, Beth Zaharoff, Director, Patient-Focused Clinical Trial Engagement of Tesaro will walk the audience through how they integrated patient input throughout multiple stages of the development process. Other discussion points include: How Tesaro is working to eliminate some of the burdens inherent in clinical trial participationWhat patient focus means to Tesaro and why/how they decided to jump in the deep endTesaro focus groups and what they learned from the experts Join us this year at the 6th annual Patients as Partners US conference, taking place March 11-12, 2019 in Philadelphia.

Keytruda in Combo with Chemo in NSCLC Dec 11, 2018

Show notes

Originally recorded at the 4th annual Immuno-Oncology 360° 2018 event, Dr Corey Langer, Director, Thoracic Oncology and Professor of Medicine for the Perelman Center for Advanced Medicine at the University of Pennsylvania, discusses data on Keytruda in combination with chemotherapy in non-small cell lung cancer. This year, the University of Pennsylvania will be represented by Dr Marco Ruella, Assistant Professor and Scientific Director Lymphoma Program, Division of Hematology and Oncology, Department of Medicine and Center for Cellular Immunotherapies. Dr Ruella will be discussing the next steps for CAR-T therapy for cancer on day three during the Next Generation Cell Therapy Plenary To join in on the discussion at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY!

Future Value Generation in Immuno-Oncology Dec 05, 2018

Show notes

In this podcast, originally recorded at the 4th annual annual Immuno-Oncology 360° 2018 event, Dr Axel Hoos, SVP, Oncology R&D, GSK, led a panel on The Future Value Generation in IO. Dr Hoos was joined by expert analyst Dr Andrew Baum, Head of Global Healthcare and Managing Director of Equity Research for Citi along with Dr David Grayzel, Partner of Atlas Venture, Dr Simeon George, Partner of SR One and Mark Simon, Partner of Torreya Partners. Key discussion points included: What is the most important IO event or trend that will carry us forward and shape the IO space?With the ever expanding range of indications, what is next and how do we get there?What have we learned from precision medicine and how can that be applied to IO?Which biomarker is next that will follow PDL1 and that will help guide the field in patient selection?With the many opportunities now with modalities, what do you think is a valuable next modality that could be important?With the maturing and evolving IO landscape, has that changed investment sentiment? For the latest news in immunotherapy, join us at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY.

Reflections of the Cancer Moonshot and Future of the Biden Cancer Initiative Dec 04, 2018

Show notes

Greg Simon, President at the Biden Cancer Initiative and Former Executive Director of the White House Cancer Task Force will reflect on the work of the Cancer Moonshot. Which provided the leadership to harness the millions of scientists and patients, powerful new therapies, and cultural changes needed to double our rate of progress against cancer. He will also provide a progress report on the Biden Cancer Initiative which is now continuing this movement to double our rate of progress in preventing, detecting, diagnosing and treating cancer. This session was presented at the 4th annual Immuno-Oncology 360 conference in February 2018. For the latest news in immunotherapy, join us at the 5th annual IO360 conference taking place February 6-8, 2019 in New York, NY.

Balancing Benefit and Toxicity from Immunotherapeutics Dec 04, 2018

Show notes

Jeffrey Weber, Deputy Director at Laura and Isaac Perlmutter Cancer Center and Co-director of Melanoma Program and Head of Experimental Therapeutics at NYU Langone Medical Center, discusses the day to day management of, and the science around, IO adverse events that may help us understand how these drugs work. Including: The need to educate physicians about management of immune related adverse events with increasing penetration of checkpoint inhibitors into the communityThe relationship of these adverse events to outcome with checkpoint inhibitionThe relation of adverse events to other autoimmune diseases that are similar in nature This session was presented at the 4th annual Immuno-Oncology 360 conference in February 2018. For more information on the IO360 conference and details for the 5th annual program taking place February 6-8, 2019 in New York, NY, please visit io360summit.com.

The BioCentury Report on Immuno-Oncology Industry Trends Nov 28, 2018

Show notes

The BioCentury Report on Industry Trends covers how companies and academic investigators are driving innovations within immuno-oncology, including new targets, modalities and technologies, to address some of the field's biggest challenges. Some topics include: The broadening trend to harness the innate and adaptive arms of the immune system for immunotherapiesNew cell types beyond CAR-T and traditional T-cellsCombination strategies for neoantigens and other targets from the earliest stages of drug development This presentation, presented by Simone Fishburn, PhD, Editor, BioCentury Innovations, was given at the 4th Annual Immuno-Oncology 360° Event on February 7-9, 2018 in New York City. Find more information at io360summit.com

5th Annual Immuno-Oncology 360˚: 12 minutes of What to Expect Nov 19, 2018

Show notes

IO360° brings together science, clinical and business under one roof to accelerate treatments to fight a wider range of cancers. This brief podcast gives you an overview on what you can expect at IO360°. The three-day summit features 10 plenary sessions with over 80 speakers and includes ten plus hours of networking. There will be over 450 attendees. Key benefits: Access to KOLs driving the sciencePartnership opportunities with all stakeholders in Immuno-OncologyPresentations on the latest data affecting the science, clinical and business advancements in Immuno-Oncology IO360° is chaired by Dr Andrew Baum, Citi along with Dr Axel Hoos, GlaxoSmithKline and Dr James Gulley, National Cancer Institute. Learn more information about IO360° at www.io360summit.com Take 10% off the regitration fee with code RADIO

Partnership Opportunities in Drug Delivery 2018: What to Expect 5 Min Podcast Sep 08, 2018

Show notes

The 8th Annual Partnership Opportunities in Drug Delivery (PODD) event will take place on October 18-19, 2018. PODD is designed with 3 purposes: To present a strategic level program for pharma and biotech biz development professionals with a thorough overview of the latest drug delivery technologies available along with an update on deals and opportunities.To provide drug delivery with a platform to present their technologies and get the latest insights on what the delivery and formulation needs are.To offer ample networking time, facilities and services for one-on-one meetings to establish new business contacts and enhance existing ones. PODD is chaired by Dr Barbara Lueckel, Head of Research and Technologies Partnering at Roche. MIT's Dr Robert Langer and Polaris' Amy Schulman, two dynamic entrepreneurs in biotech are the opeining keynotes in a fireside chat. Justin Wright, PhD, Global Head of Innovation, Novartis will provide an industry keynote. Also, Jeffrey Karp, PhD keynotes with Stories from Bioinspiration to drug delivery. Choice of delivery tech tracks and includes partnering support. More info: theconferenceforum.org Host: Valerie Bowling, PODD Director

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected